Please login to the form below

Not currently logged in
Email:
Password:

Fabrazyme

This page shows the latest Fabrazyme news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Gene therapy trend grows, new rival for Fabrazyme. Orchard Therapeutics raises $150m to advance gene therapy pipeline. ... Galafold (migalastat) will be the first new Fabry treatment on the US market in more than 15 years, and will compete with

Latest news

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta).

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    Despite initial uncertainty over its clinical effectiveness, the cost-effectiveness watchdog concluded that Galafold provides enough similar benefits to current enzyme replacement therapies (ERT), such as Sanofi's Fabrazyme (agalsidase beta)

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    The drug could offer a patient-friendly alternative to injectable Fabry therapies such as Sanofi/Genzyme's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).

  • Sanofi rare disease drug a breakthrough, says FDA Sanofi rare disease drug a breakthrough, says FDA

    Genzyme has built the core of its business by focusing on this group, developing big-selling brands such as Gaucher therapy Cerezyme (imiglucerase alfa), Fabrazyme (agalsidase beta) for Fabry disease and

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics